Nevirapine Amarox

Nevirapine, the active ingredient in Nevirapine Amarox, is a non‑nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It is employed in combination antiretroviral regimens to treat HIV‑1 infection in adults, adolescents and children over two years of age, helping to suppress viral replication and improve immune function.

GNH USA supplies Nevirapine Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Nevirapine is an NNRTI used in antiretroviral therapy to target HIV‑1 replication.

- HIV‑1 infection: reduces viral load when combined with other antiretroviral agents. - Mother‑to‑child transmission prevention: part of regimens that lower the risk of perinatal HIV transmission. - Treatment‑experienced HIV‑1 infection: provides an alternative option for patients with resistance to other drug classes.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions that may appear on the torso or limbs. - Nausea: transient stomach discomfort often occurring after the first doses. - Fatigue: generalized tiredness without a clear cause. - Headache: mild to moderate head pain that may improve with rest.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement. - Hepatic failure: signs include jaundice, elevated liver enzymes, and possible liver dysfunction. - Hypersensitivity reactions: fever, eosinophilia, and systemic symptoms requiring immediate medical attention. - Neutropenia: marked reduction in white blood cells increasing infection risk.

Before initiating nevirapine therapy, clinicians should evaluate several safety considerations to minimize risk.

- Liver function monitoring: assess baseline transaminases and repeat tests regularly during treatment. - Rash surveillance: examine patients for early skin changes and discontinue if severe. - Drug interaction review: avoid concomitant use with strong CYP3A inducers that lower nevirapine levels. - Hepatitis co‑infection caution: use with care in patients with active hepatitis B or C infection. - Pregnancy and breastfeeding assessment: discuss potential risks and benefits with the patient. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nevirapine interacts with several medicines, influencing its plasma concentration or the effect of the co‑administered drug.

Major Interactions (Avoid): - Rifampicin: strong enzyme inducer that markedly reduces nevirapine exposure. - St. John’s wort: herbal CYP3A inducer that can lower nevirapine levels. - Protease inhibitors (e.g., ritonavir): may increase nevirapine concentrations and raise toxicity risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: nevirapine can reduce hormonal efficacy, requiring additional contraceptive measures. - Azole antifungals (e.g., ketoconazole): may increase nevirapine levels, necessitating liver function monitoring.